Journal article
Extreme deviations from the normative model reveal cortical heterogeneity and associations with negative symptom severity in first-episode psychosis from the OPTiMiSE and GAP studies
A Worker, P Berthert, AJ Lawrence, SM Kia, C Arango, R Dinga, S Galderisi, B Glenthøj, RS Kahn, A Leslie, RM Murray, CM Pariante, C Pantelis, M Weiser, I Winter-van Rossum, P McGuire, P Dazzan, AF Marquand
Translational Psychiatry | SPRINGERNATURE | Published : 2023
Abstract
There is currently no quantifiable method to predict long-term clinical outcomes in patients presenting with a first episode of psychosis. A major barrier to developing useful markers for this is biological heterogeneity, where many different pathological mechanisms may underly the same set of symptoms in different individuals. Normative modelling has been used to quantify this heterogeneity in established psychotic disorders by identifying regions of the cortex which are thinner than expected based on a normative healthy population range. These brain atypicalities are measured at the individual level and therefore potentially useful in a clinical setting. However, it is still unclear whethe..
View full abstractGrants
Awarded by Department of Health and Social Care
Funding Acknowledgements
This study was supported by grant number 'BRAINCHART', 215698/Z/19/Z from the Wellcome Trust Innovator Award (Dr Andre Marquand). The OPTiMiSE study was funded by the European Commission Seventh Framework Program (HEALTH-F2-2010-242114). Research at the London site was supported by the Department of Health via the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. CP was supported by a NHMRC Senior Principal Research Fellowship (1105825), and NHMRC L3 Investigator Grant (1196508). Dr. Arango was supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), co-financed by the European Union, ERDF Funds from the European Commission, "A way of making Europe", financed by the European Union - NextGenerationEU (PMP21/00051), CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement No.101034377), Project AIMS-2-TRIALS (Grant agreement No 777394), Horizon Europe, the National Institute of Mental Health of the National Institutes of Health under Award Number 1U01MH124639-01 (Project ProNET) and Award Number 5P50MH115846-03 (project FEP-CAUSAL), Fundacion Familia Alonso, and Fundacion Alicia Koplowitz.